Login

(E)-3,4,5-Trimethoxycinnamic acid

CAT:
804-HY-W050162-03
Size:
100 mg
Price:
Ask
For price, please contact [email protected]
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
(E)-3,4,5-Trimethoxycinnamic acid - image 1

(E)-3,4,5-Trimethoxycinnamic acid

  • CAS Number: 20329-98-0
  • UNSPSC Description: (E)-3,4,5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3,4,5-Trimethoxycinnamic acid is an orally active and potent GABAA/BZ receptor agonist. (E)-3,4,5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT2C and 5-HT1A receptor, with IC50 values of 2.5 and 7.6 μM, respectively. (E)-3,4,5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3,4,5-Trimethoxycinnamic acid can be used for the research of insomnia, headache and epilepsy[1][2][3].
  • Target Antigen: 5-HT Receptor; GABA Receptor
  • Type: Reference compound
  • Related Pathways: GPCR/G Protein;Membrane Transporter/Ion Channel;Neuronal Signaling
  • Applications: Neuroscience-Neuromodulation
  • Field of Research: Neurological Disease
  • Assay Protocol: https://www.medchemexpress.com/e-3-4-5-trimethoxycinnamic-acid.html
  • Purity: 99.95
  • Solubility: DMSO : 100 mg/mL (ultrasonic)
  • Smiles: O=C(O)/C=C/C1=CC(OC)=C(OC)C(OC)=C1
  • Molecular Weight: 238.239
  • References & Citations: [1]Zhao Z, et al. Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives. Eur J Med Chem. 2019 Jul 1;173:213-227.|[2]Chen CY, et al. 3,4,5-Trimethoxycinnamic acid, one of the constituents of Polygalae Radix exerts anti-seizure effects by modulating GABAAergic systems in mice. J Pharmacol Sci. 2016 May;131(1):1-5. |[3]Lee CI, et al. 3,4,5-Trimethoxycinnamic acid (TMCA), one of the constituents of Polygalae Radix enhances pentobarbital-induced sleeping behaviors via GABAAergic systems in mice. Arch Pharm Res. 2013 Oct;36(10):1244-51.
  • Shipping Conditions: Room Temperature
  • Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information: No Development Reported